Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual 26th Annual Congress of the European Hematology Association. Phase I/II Data for SEL24 (MEN1703) presented by development partner Menarini
RVU120 (CDK8/19 inhibitor): Acceptable safety profile and two clinically relevant responses were observed in the Ph I dose escalation study in the first five AML and high risk MDS patients treated: one complete response (CR) and one erythroid response
SEL24/MEN1703…
